{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:26:11Z","timestamp":1791595571629,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thermal neutrons generated in the body during proton beam therapy (PBT) can be used to cause boron neutron capture reactions and have recently been proposed as neutron capture enhanced PBT (NCEPBT). However, the cell killing effect of NCEPBT remains underexplored. Here, we show an increase in the cell killing effect of NCEPBT. Using Monte Carlo simulations, we showed that neutrons generated by proton beam irradiation are uniformly spread on tissue culture plates. Human salivary gland tumor cell line (HSG), human osteosarcoma cell line (MG63), human tongue squamous cell carcinoma cell line (SAS), and human malignant melanoma cell line (G-361) were irradiated with X-rays, proton beams, and proton beams with <jats:sup>10<\/jats:sup>B-enriched  boronophenylalanine (boron concentration of 20 and 80 ppm). The relative biological effectiveness (RBE) values of proton beams alone, proton beams with 20 ppm boron, and proton beams with 80 ppm boron for HSG, MG63, SAS, and G-361 were 1.02, 1.07, and 1.23; 1.01, 1.08, and 1.44; 1.05, 1.09, and 1.46; and 1.04, 1.13, and 1.63, respectively. NCEPBT with high boron concentration showed high RBE and a high sensitizing effect. Our results confirm an increase in the cell killing effect of NCEPBT, should aid in its clinical use, and warrant its further investigation.<\/jats:p>","DOI":"10.1038\/s41598-024-79045-3","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T12:03:37Z","timestamp":1731931417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased cell killing effect in neutron capture enhanced proton beam therapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Shintaro","family":"Shiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yagihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Tokuuye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"79045_CR1","doi-asserted-by":"crossref","unstructured":"Paganetti, H. Proton Beam Therapy (IOP Publishing, 2017).","DOI":"10.1088\/978-0-7503-1370-4ch1"},{"key":"79045_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.meddos.2007.04.008","volume":"33","author":"X Wang","year":"2008","unstructured":"Wang, X. et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med. Dosim. 33, 259\u2013267 (2008).","journal-title":"Med. Dosim"},{"key":"79045_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","volume":"65","author":"JY Chang","year":"2006","unstructured":"Chang, J. Y. et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 65, 1087\u20131096 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"79045_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ijrobp.2018.02.022","volume":"101","author":"C Nantavithya","year":"2018","unstructured":"Nantavithya, C. et al. Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 101, 558\u2013563 (2018).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"79045_CR5","doi-asserted-by":"publisher","first-page":"20190237","DOI":"10.1259\/bjr.20190237","volume":"93","author":"DC Weber","year":"2020","unstructured":"Weber, D. C. et al. Proton therapy for brain tumours in the area of evidence-based medicine. Br. J. Radiol. 93, 20190237 (2020).","journal-title":"Br. J. Radiol."},{"key":"79045_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11912-020-0889-9","volume":"22","author":"O Siddiqui","year":"2020","unstructured":"Siddiqui, O., Pollock, A., Samanta, S., Kaiser, A. & Molitoris, J. K. Proton Beam therapy in liver malignancies. Curr. Oncol. Rep. 22, 30 (2020).","journal-title":"Curr. Oncol. Rep."},{"key":"79045_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/2193-1801-3-128","volume":"3","author":"SI Masunaga","year":"2014","unstructured":"Masunaga, S. I. et al. The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy. Springerplus. 3, 128 (2014).","journal-title":"Springerplus"},{"key":"79045_CR8","doi-asserted-by":"crossref","unstructured":"Wongthai, P. et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, istransported by ATB0,+, LAT1 and LAT2 Cancer Sci. 106, 279\u2013286 (2015).","DOI":"10.1111\/cas.12602"},{"key":"79045_CR9","doi-asserted-by":"publisher","first-page":"096702","DOI":"10.1088\/0034-4885\/79\/9\/096702","volume":"79","author":"M Durante","year":"2016","unstructured":"Durante, M. & Paganetti, H. Nuclear physics in particle therapy: A review. Rep. Prog Phys. 79, 096702 (2016).","journal-title":"Rep. Prog Phys."},{"key":"79045_CR10","first-page":"661","volume":"1","author":"G Battistoni","year":"2016","unstructured":"Battistoni, G., Mattei, I. & Muraro, S. Nuclear physics and particle therapy. Adv. Phys. X. 1, 661\u2013686 (2016).","journal-title":"Adv. Phys. X"},{"key":"79045_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2022.04.027","volume":"172","author":"M Dell\u2019Oro","year":"2022","unstructured":"Dell\u2019Oro, M. et al. Lifetime attributable risk of radiation induced second primary cancer from scattering and scanning proton therapy - A model for out-of-field organs of paediatric patients with cranial cancer. Radiother Oncol. 172, 65\u201375 (2022).","journal-title":"Radiother Oncol."},{"key":"79045_CR12","doi-asserted-by":"publisher","first-page":"16257","DOI":"10.1038\/s41598-018-34643-w","volume":"8","author":"M Safavi-Naeini","year":"2018","unstructured":"Safavi-Naeini, M. et al. Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons. Sci. Rep. 8, 16257 (2018).","journal-title":"Sci. Rep."},{"key":"79045_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/00223131.2023.2275736","volume":"61","author":"T Sato","year":"2024","unstructured":"Sato, T. et al. Recent improvements of the particle and heavy ion transport code system \u2013 PHITS version 3.33. J. Nucl. Sci. Technol. 61, 127\u2013135 (2024).","journal-title":"J. Nucl. Sci. Technol."},{"key":"79045_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/18811248.2011.9711675","volume":"48","author":"K Shibata","year":"2011","unstructured":"Shibata, K. et al. JENDL-4.0: A new library for nuclear science and engineering. J. Nucl. Sci. Technol. 48, 1\u201330 (2011).","journal-title":"J. Nucl. Sci. Technol."},{"key":"79045_CR15","doi-asserted-by":"publisher","first-page":"110187","DOI":"10.1016\/j.apradiso.2022.110187","volume":"184","author":"AH Alinejad","year":"2022","unstructured":"Alinejad, A. H., Kakavand, T., Aboudzadeh Rovais, M. R. & Kakaei, S. Study of the 199Au nanoparticles production parameters via irradiation of platinum target by using thermal neutrons. Appl. Radiat. Isot. 184, 110187 (2022).","journal-title":"Appl. Radiat. Isot."},{"key":"79045_CR16","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/1078-0432.CCR-05-1907","volume":"12","author":"T Nakano","year":"2006","unstructured":"Nakano, T. et al. Carbon Beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin. Cancer Res. 12, 2185\u20132190 (2006).","journal-title":"Clin. Cancer Res."},{"key":"79045_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/cancers13051099","volume":"13","author":"S Shiba","year":"2021","unstructured":"Shiba, S. et al. Impact of carbon ion radiotherapy on inoperable bone sarcoma. Cancers. 13, 1099 (2021).","journal-title":"Cancers"},{"key":"79045_CR18","doi-asserted-by":"publisher","first-page":"109407","DOI":"10.1016\/j.apradiso.2020.109407","volume":"169","author":"T Fujimoto","year":"2021","unstructured":"Fujimoto, T. et al. BNCT for primary synovial sarcoma. Appl. Radiat. Isot. 169, 109407 (2021).","journal-title":"Appl. Radiat. Isot."},{"key":"79045_CR19","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.21873\/anticanres.16684","volume":"43","author":"S Shiba","year":"2023","unstructured":"Shiba, S., Kawashima, M., Okamoto, M. & Ohno, T. Dose distribution degradation of carbon-ion radiotherapy caused by tumor cell-specific relative biological effectiveness of osteosarcoma: A simulation study using in vitro experimental results. Anticancer Res. 43, 4873\u20134878 (2023).","journal-title":"Anticancer Res."},{"key":"79045_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2307\/3579556","volume":"146","author":"J Capala","year":"1996","unstructured":"Capala, J., Makar, M. S. & Coderre, J. A. Accumulation of boron in malignant and normal cells incubated in vitro with boronophenylalanine, mercaptoborane or boric acid. Radiat. Res. 146, 554\u2013560 (1996).","journal-title":"Radiat. Res."},{"key":"79045_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/jrr\/rrac077","volume":"64","author":"T Watanabe","year":"2023","unstructured":"Watanabe, T., Sanada, Y., Hattori, Y. & Suzuki, M. Correlation between the expression of LAT1 in cancer cells and the potential efficacy of boron neutron capture therapy. J. Radiat. Res. 64, 91\u201398 (2023).","journal-title":"J. Radiat. Res."},{"key":"79045_CR22","doi-asserted-by":"publisher","first-page":"109257","DOI":"10.1016\/j.apradiso.2020.109257","volume":"165","author":"T Andoh","year":"2020","unstructured":"Andoh, T. et al. Preclinical study of boron neutron capture therapy for bone metastasis using human breast cancer cell lines. Appl. Radiat. Isot. 165, 109257 (2020).","journal-title":"Appl. Radiat. Isot."},{"key":"79045_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.radonc.2020.11.001","volume":"155","author":"K Hirose","year":"2021","unstructured":"Hirose, K. et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 155, 182\u2013187 (2021).","journal-title":"Radiother Oncol."},{"key":"79045_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF02699940","volume":"62","author":"J Capala","year":"2003","unstructured":"Capala, J. et al. Boron neutron capture therapy for glioblastoma multiforme: Clinical studies in Sweden. J. Neurooncol. 62, 135\u2013144 (2003).","journal-title":"J. Neurooncol."},{"key":"79045_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijrobp.2024.02.052","volume":"120","author":"N Howell","year":"2024","unstructured":"Howell, N. et al. Neutron capture enhances dose and reduces cancer cell viability in and out of beam during Helium and carbon ion therapy. Int. J. Radiat. Oncol. Biol. Phys. 120, 229\u2013242 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79045-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79045-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79045-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:15:45Z","timestamp":1732241745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79045-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79045"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79045-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Boronophenylalanine used in this study was provided by Stella Pharma Corporation (Japan). Tatsuya Ohno received research funding from Hitachi. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28484"}}